GlassScriptPhysician profile
Swati Sehgal
NPI 1992961213
$1,206.73
in general payments reported to CMS, 2019-2025
23 companies · $94.19 in 2025
The $94.19 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.58 · 2020: $92.26 · 2021: $121 · 2022: $335 · 2023: $550 · 2025: $94.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.56 |
| Education | $180.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $224.55 | 2020-2023 | Lumakras, Kyprolis |
| Novartis Pharmaceuticals Corporation | $221.38 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $135.66 | 2023 | Lynparza |
| Lilly USA, LLC | $94.19 | 2025 | |
| Pfizer INC. | $46.25 | 2022-2023 | |
| Celgene Corporation | $45.00 | 2022-2023 | Reblozyl |
| Myriad Genetic Laboratories, INC. | $43.14 | 2023 | Myrisk |
| Aveo Pharmaceuticals, INC. | $42.58 | 2021-2022 | |
| Daiichi Sankyo INC. | $41.72 | 2023 | Injectafer, Enhertu |
| Foundation Medicine, INC. | $35.07 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $28.79 | 2023 | Epkinly |
| Progenics Pharmaceuticals, INC. | $28.73 | 2023 | Pylarify |
| Novocure INC. | $26.30 | 2023 | Optune |
| Jazz Pharmaceuticals INC. | $24.81 | 2023 | Zepzelca |
| E.R. Squibb & Sons, L.L.C. | $24.26 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $23.98 | 2022 | |
| Karyopharm Therapeutics INC. | $22.72 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2023 | Libtayo |
| Array Biopharma INC | $19.92 | 2023 | Mektovi, Lorbrena, Braftovi |
| Janssen Pharmaceuticals, INC | $16.14 | 2023 | Xarelto |
| Medtronic Vascular, INC. | $14.58 | 2019 | |
| Taiho Oncology, INC. | $12.93 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Sehgal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.